Lovastatin (Synonyms: 洛伐他汀; Mevinolin)

目錄號(hào): HY-N0504 純度: 99.64%: FAQs
Data Sheet SDS COA 產(chǎn)品使用指南

摩爾計(jì)算器

Lovastatin是一種用于降低膽固醇的細(xì)胞滲透性的 HMG-CoA還原酶抑制劑。

MCE 的所有產(chǎn)品僅用作科學(xué)研究或藥證申報(bào)，我們不為任何個(gè)人用途提供產(chǎn)品和服務(wù)

Lovastatin Chemical Structure

CAS No. : 75330-75-5

1. 客戶無需承擔(dān)相應(yīng)的運(yùn)輸費(fèi)用。

2. 同一機(jī)構(gòu)（單位）同一產(chǎn)品試用裝僅限申領(lǐng)一次，同一機(jī)構(gòu)（單位）一年內(nèi)

可免費(fèi)申領(lǐng)三個(gè)不同產(chǎn)品的試用裝。

3. 試用裝只面向終端客戶。

規(guī)格	價(jià)格	是否有貨
10 mM * 1 mL in DMSO	￥500	In-stock
50 mg	￥599	In-stock
100 mg	￥871	In-stock
200 mg	￥1200	In-stock
500 mg		詢價(jià)
1 g		詢價(jià)

or 大包裝詢價(jià)

* Please select Quantity before adding items.

Customer Review

Other Forms of Lovastatin:

Lovastatin (Standard) In-stock
Epi Lovastatin-d3 詢價(jià)
Lovastatin-d₉ 詢價(jià)
Lovastatin-d₃ 詢價(jià)

MCE 顧客使用本產(chǎn)品發(fā)表的 22 篇科研文獻(xiàn)

•Signal Transduct Target Ther. 2023 May 10;8(1):183. [Abstract]
•Cell Metab. 2020 Apr 7;31(4):741-754.e5. [Abstract]
•Nat Commun. 2024 Jul 26;15(1):6311. [Abstract]
•Nucleic Acids Res. 2023 Sep 22;gkad759. [Abstract]
•Nat Commun. 2023 May 26;14(1):3050. [Abstract]
•Redox Biol. 2022 Feb;49:102207. [Abstract]

•Cell Death Dis. 2019 Apr 11;10(4):327. [Abstract]
•Ecotoxicol Environ Saf. 2024 Jul 18:282:116738. [Abstract]
•Cell Biosci. 2023 Oct 3;13(1):186. [Abstract]
•JCI Insight. 2022 Aug 9;e161940. [Abstract]
•Pharmaceutics. 2024 May 29.
•J Hepatocell Carcinoma. 2023 Dec 5.
•Antiviral Res. 2022 Dec 15;209:105497. [Abstract]
•Front Bioeng Biotechnol. 2022 Mar 17;10:826093. [Abstract]
•Front Cell Dev Biol. 2022 Mar 3;10:806081. [Abstract]
•Front Cell Dev Biol. 2020 May 28;8:404. [Abstract]
•Cell Cycle. 2019 Dec;18(23):3337-3350. [Abstract]
•ACS Omega. 2020 Nov 15;5(46):29935-29942. [Abstract]
•PLoS Negl Trop Dis. 2019 Aug 20;13(8):e0007681. [Abstract]
•Biochem Biophys Res Commun. 2019 May 14;512(4):736-741. [Abstract]
•J Gen Virol. 2019 Feb;100(2):156-165. [Abstract]
•University of New Hampshire. Science in Biochemistry. 2021 Oct.

: Lovastatin purchased from MCE. Usage Cited in: Antiviral Res. 2022 Dec 15;209:105497. [Abstract]; Pretreatment with AY9944 (15, 30 μM), U18666A (5, 10 μM), lovastatin (5, 10 μM) and MβCD for 2 h can all significantly reduce the level of EV-A71 VP1 protein in HCT-8 cell.

Lovastatin 相關(guān)產(chǎn)品

•相關(guān)化合物庫:

•同靶點(diǎn)產(chǎn)品:

•同靶點(diǎn)蛋白產(chǎn)品:

生物活性
純度 & 產(chǎn)品資料
參考文獻(xiàn)

生物活性

Lovastatin is a cell-permeable HMG-CoA reductase inhibitor used to lower cholesterol.

IC₅₀ & Target

HMG-CoA reductase^[1]

細(xì)胞效力
(Cellular Effect)

Cell Line	Type	Value	Description	References
A549	IC₅₀	11.4 μM Compound: 1	Cytotoxicity against human A549 cells after 72 hrs by MTT assay Cytotoxicity against human A549 cells after 72 hrs by MTT assay	[PMID: 23570542]
A549	IC₅₀	19.8 μM Compound: 1	Inhibition of HMG-CoA reductase in human A549 cells after 5 mins by spectrophotometric analysis Inhibition of HMG-CoA reductase in human A549 cells after 5 mins by spectrophotometric analysis	[PMID: 23570542]
HepG2	IC₅₀	37 nM Compound: mevinolin (lactone) 2	Concentration required to inhibit HMG-CoA reductase by 50% was determined in Hep G2 cell line Concentration required to inhibit HMG-CoA reductase by 50% was determined in Hep G2 cell line	[PMID: 1527791]
HepG2	IC₅₀	50 nM Compound: 1b (Mevinolin)	Inhibition of cellular HMG-CoA reductase in cultures of human HEP G2 cells, determined by decreased incorporation of sodium [14C]acetate into cholesterol. Inhibition of cellular HMG-CoA reductase in cultures of human HEP G2 cells, determined by decreased incorporation of sodium [14C]acetate into cholesterol.	[PMID: 2296036]
HepG2	IC₅₀	8.3 μM Compound: Lovastatin	Lipid lowering activity in human HepG2 cells assessed as decrease in oleic acid elicited lipid accumulation after 6 hrs by oil-red O staining method Lipid lowering activity in human HepG2 cells assessed as decrease in oleic acid elicited lipid accumulation after 6 hrs by oil-red O staining method	[PMID: 26169125]
HES	IC₅₀	13 nM Compound: mevinolin (lactone) 2	Concentration required to inhibit HMG-CoA reductase by 50% was determined in HES 9 cell line Concentration required to inhibit HMG-CoA reductase by 50% was determined in HES 9 cell line	[PMID: 1527791]
Hs68	IC₅₀	23.2 μM Compound: 1	Cytotoxicity against human HS68 cells after 72 hrs by MTT assay Cytotoxicity against human HS68 cells after 72 hrs by MTT assay	[PMID: 23570542]
HT-29	IC₅₀	46.8 μM Compound: Lovastatin	Growth inhibition of human HT29 cells after 96 hrs by MTS assay Growth inhibition of human HT29 cells after 96 hrs by MTS assay	[PMID: 17472962]
KB	IC₅₀	15.6 μM Compound: 2	Cytotoxicity against human KB cells by resazurin microplate assay Cytotoxicity against human KB cells by resazurin microplate assay	[PMID: 27228159]
LS180	IC₅₀	25.3 μM Compound: Lovastatin	Growth inhibition of human LS180 cells after 96 hrs by MTS assay Growth inhibition of human LS180 cells after 96 hrs by MTS assay	[PMID: 17472962]
MCF7	IC₅₀	> 40 μM Compound: 1	Cytotoxicity against human MCF7 cells assessed as growth inhibition after 24 to 48 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as growth inhibition after 24 to 48 hrs by MTT assay	[PMID: 27756564]
MDA-MB-231	IC₅₀	> 40 μM Compound: 1	Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 24 to 48 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 24 to 48 hrs by MTT assay	[PMID: 27756564]
MEF	IC₅₀	35 μM Compound: 1	Cytotoxicity against mouse MEF cells after 72 hrs by MTT assay Cytotoxicity against mouse MEF cells after 72 hrs by MTT assay	[PMID: 23570542]
PC-3	IC₅₀	5.4 μM Compound: 1	Cytotoxicity against human PC3 cells assessed as growth inhibition after 48 hrs by SRB assay Cytotoxicity against human PC3 cells assessed as growth inhibition after 48 hrs by SRB assay	[PMID: 27756564]
SW480	IC₅₀	7.1 μM Compound: Lovastatin	Growth inhibition of human SW480 cells after 96 hrs by MTS assay Growth inhibition of human SW480 cells after 96 hrs by MTS assay	[PMID: 17472962]
T47D	IC₅₀	> 40 μM Compound: 1	Cytotoxicity against human T47D cells assessed as growth inhibition after 24 to 48 hrs by MTT assay Cytotoxicity against human T47D cells assessed as growth inhibition after 24 to 48 hrs by MTT assay	[PMID: 27756564]
THP-1	IC₅₀	8 μg/mL Compound: Lovastatin	Inhibition of sICAM1/LFA1 interaction-mediated human THP1 cell adhesion after 1 hr by ELISA Inhibition of sICAM1/LFA1 interaction-mediated human THP1 cell adhesion after 1 hr by ELISA	[PMID: 18672369]

體外研究
(In Vitro)

Lovastatin (10 μM；72 hours) 有效降低 HepG2 細(xì)胞活力^[2]。
Lovastatin (10 μM；48 hours) 誘導(dǎo) HepG2 細(xì)胞凋亡^[2]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[2]

Cell Line:	HepG2 cells
Concentration:	10 μM
Incubation Time:	72 hours
Result:	Efficiently reduced viability of HepG2 cells.

體內(nèi)研究
(In Vivo)

Lovastatin 是一種無活性內(nèi)酯，在肝臟中水解為活性 f3-羥基酸形式。這種主要代謝物是 HMG-CoA 還原酶的抑制劑。K_i 為 1 nM。Lovastatin 及其 β-羥基酸代謝物與人血漿蛋白高度結(jié)合。Lovastatin 可穿過血腦屏障和胎盤屏障^[3]。Lovastatin 可顯著降低含載脂蛋白 B 的脂蛋白，尤其是 LDL 膽固醇，并在較小程度上降低血漿甘油三酯，并略微增加 HDL 膽固醇^[4]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

分子量

404.54

Formula

C₂₄H₃₆O₅

CAS 號(hào)

75330-75-5

性狀

固體

顏色

Off-white to light yellow

中文名稱

洛伐他??；辛伐他汀EP雜質(zhì)E

結(jié)構(gòu)分類

Ketones, Aldehydes, Acids

初始來源

微生物

aspergillus terreus

運(yùn)輸條件

Room temperature in continental US; may vary elsewhere.

儲(chǔ)存方式

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

溶解性數(shù)據(jù)

細(xì)胞實(shí)驗(yàn)：

DMSO 中的溶解度 : ≥ 100 mg/mL (247.19 mM; 吸濕的 DMSO 對(duì)產(chǎn)品的溶解度有顯著影響，請(qǐng)使用新開封的 DMSO)

* "≥" means soluble, but saturation unknown.

配制儲(chǔ)備液

濃度溶劑體積質(zhì)量	1 mg	5 mg	10 mg

1 mM	2.4719 mL	12.3597 mL	24.7194 mL
5 mM	0.4944 mL	2.4719 mL	4.9439 mL
10 mM	0.2472 mL	1.2360 mL	2.4719 mL

查看完整儲(chǔ)備液配制表

* 請(qǐng)根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲(chǔ)備液；一旦配成溶液，請(qǐng)分裝保存，避免反復(fù)凍融造成的產(chǎn)品失效。
儲(chǔ)備液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C儲(chǔ)存時(shí)，請(qǐng)?jiān)?個(gè)月內(nèi)使用，-20°C儲(chǔ)存時(shí)，請(qǐng)?jiān)?個(gè)月內(nèi)使用。

摩爾計(jì)算器
稀釋計(jì)算器

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

濃度 _(start)

體積 _(start)

濃度 _(final)

體積 _(final)

動(dòng)物實(shí)驗(yàn)：

請(qǐng)根據(jù)您的實(shí)驗(yàn)動(dòng)物和給藥方式選擇適當(dāng)?shù)娜芙夥桨浮?

以下溶解方案都請(qǐng)先按照 In Vitro 方式配制澄清的儲(chǔ)備液，再依次添加助溶劑：
——為保證實(shí)驗(yàn)結(jié)果的可靠性，澄清的儲(chǔ)備液可以根據(jù)儲(chǔ)存條件，適當(dāng)保存；體內(nèi)實(shí)驗(yàn)的工作液，建議您現(xiàn)用現(xiàn)配，當(dāng)天使用；
以下溶劑前顯示的百分比是指該溶劑在您配制終溶液中的體積占比；如在配制過程中出現(xiàn)沉淀、析出現(xiàn)象，可以通過加熱和/或超聲的方式助溶

方案一

請(qǐng)依序添加每種溶劑： 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (6.18 mM); 澄清溶液

此方案可獲得 ≥ 2.5 mg/mL（飽和度未知）的澄清溶液。
以 1 mL 工作液為例，取 100 μL 25.0 mg/mL 的澄清 DMSO 儲(chǔ)備液加到 400 μL PEG300 中，混合均勻；再向上述體系中加入 50 μL Tween-80，混合均勻；然后再繼續(xù)加入 450 μL 生理鹽水定容至 1 mL。
生理鹽水的配制：將 0.9 g 氯化鈉，溶解于 ddH?O 并定容至 100 mL，可以得到澄清透明的生理鹽水溶液。
方案二

請(qǐng)依序添加每種溶劑： 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (6.18 mM); 澄清溶液

此方案可獲得 ≥ 2.5 mg/mL（飽和度未知）的澄清溶液。
以 1 mL 工作液為例，取 100 μL 25.0 mg/mL 的澄清 DMSO 儲(chǔ)備液加到 900 μL 20% 的 SBE-β-CD 生理鹽水水溶液中，混合均勻。
2 g SBE-β-CD（磺丁基醚 β-環(huán)糊精）粉末定容于 10 mL 的生理鹽水中，完全溶解至澄清透明。
方案三

請(qǐng)依序添加每種溶劑： 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (6.18 mM); 澄清溶液

此方案可獲得 ≥ 2.5 mg/mL（飽和度未知）的澄清溶液，此方案實(shí)驗(yàn)周期在半個(gè)月以上的動(dòng)物實(shí)驗(yàn)酌情使用。
以 1 mL 工作液為例，取 100 μL 25.0 mg/mL 的澄清 DMSO 儲(chǔ)備液加到 900 μL玉米油中，混合均勻。

動(dòng)物溶解方案計(jì)算器

請(qǐng)輸入動(dòng)物實(shí)驗(yàn)的基本信息：

給藥劑量

mg/kg

動(dòng)物的平均體重

每只動(dòng)物的給藥體積

μL

動(dòng)物數(shù)量

只

由于實(shí)驗(yàn)過程有損耗，建議您多配一只動(dòng)物的量

請(qǐng)輸入您的動(dòng)物體內(nèi)配方組成：

DMSO +

Tween-80 +

Saline

如果您的動(dòng)物是免疫缺陷鼠或者體弱鼠，建議 DMSO 中的在最后工作液體系中的占比盡量不超過 2%。

方案所需 助溶劑 包括：DMSO，，均可在 MCE 網(wǎng)站選購(gòu)。，Tween 80，均可在 MCE 網(wǎng)站選購(gòu)。

計(jì)算結(jié)果

工作液所需濃度 : mg/mL

儲(chǔ)備液配制方法 : mg 藥物溶于 μL DMSO（母液濃度為 mg/mL）。

您所需的儲(chǔ)備液濃度超過該產(chǎn)品的實(shí)測(cè)溶解度，以下方案僅供參考，如有需要，請(qǐng)與 MCE 中國(guó)技術(shù)支持聯(lián)系。

動(dòng)物實(shí)驗(yàn)體內(nèi)工作液的配制方法 : 取 μL DMSO 儲(chǔ)備液，加入 μL 。 μL ，混合均勻至澄清，再加 μL Tween 80，混合均勻至澄清，再加 μL 生理鹽水。

連續(xù)給藥周期超過半月以上，請(qǐng)謹(jǐn)慎選擇該方案。

請(qǐng)確保第一步儲(chǔ)備液溶解至澄清狀態(tài)，從左到右依次添加助溶劑。您可采用超聲加熱（超聲清洗儀，建議頻次 20-40 kHz），渦旋吹打等方式輔助溶解。

純度 & 產(chǎn)品資料

純度: 99.89%

選擇批次：

Data Sheet (642 KB) SDS (418 KB)

COA (293 KB) LCMS (154 KB)

產(chǎn)品使用指南 (1538 KB)

參考文獻(xiàn)

[1]. Alberts AW, et al. Discovery, biochemistry and biology of lovastatin. Am J Cardiol. 1988 Nov 11;62(15):10J-15J. [Content Brief]

[2]. Kah J, et al. Selective induction of apoptosis by HMG-CoA reductase inhibitors in hepatoma cells and dependence on p53 expression. Oncol Rep. 2012 Sep;28(3):1077-83. [Content Brief]

[3]. Frishman WH, et al. Lovastatin: an HMG-CoA reductase inhibitor for lowering cholesterol. Med Clin North Am. 1989 Mar;73(2):437-48. [Content Brief]

[4]. Tobert JA, et al. Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors. Nat Rev Drug Discov. 2003 Jul;2(7):517-26. [Content Brief]

[5]. Ifergan I, et al. Statins reduce human blood-brain barrier permeability and restrict leukocyte migration: relevance to multiple sclerosis. Ann Neurol. 2006 Jul;60(1):45-55. [Content Brief]

Lovastatin 相關(guān)分類

完整儲(chǔ)備液配制表

可選溶劑	濃度溶劑體積質(zhì)量	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	2.4719 mL	12.3597 mL	24.7194 mL	61.7986 mL
	5 mM	0.4944 mL	2.4719 mL	4.9439 mL	12.3597 mL
	10 mM	0.2472 mL	1.2360 mL	2.4719 mL	6.1799 mL
	15 mM	0.1648 mL	0.8240 mL	1.6480 mL	4.1199 mL
	20 mM	0.1236 mL	0.6180 mL	1.2360 mL	3.0899 mL
	25 mM	0.0989 mL	0.4944 mL	0.9888 mL	2.4719 mL
	30 mM	0.0824 mL	0.4120 mL	0.8240 mL	2.0600 mL
	40 mM	0.0618 mL	0.3090 mL	0.6180 mL	1.5450 mL
	50 mM	0.0494 mL	0.2472 mL	0.4944 mL	1.2360 mL
	60 mM	0.0412 mL	0.2060 mL	0.4120 mL	1.0300 mL
	80 mM	0.0309 mL	0.1545 mL	0.3090 mL	0.7725 mL
	100 mM	0.0247 mL	0.1236 mL	0.2472 mL	0.6180 mL

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Lovastatin75330-75-5Mevinolin洛伐他汀辛伐他汀EP雜質(zhì)EHMG-CoA Reductase (HMGCR)AutophagyFerroptosisInhibitorinhibitorinhibit

您最近查看的產(chǎn)品:

產(chǎn)品名稱：

* 需求量：

* 客戶姓名：

* Email：

* 電話：

* 公司或機(jī)構(gòu)名稱：

留言給我們：

MedChemExpress (MCE) 只為有資質(zhì)的科研機(jī)構(gòu)、醫(yī)藥企業(yè)基于科學(xué)研究或藥證申報(bào)的用途提供醫(yī)藥研發(fā)服務(wù)，不為任何個(gè)人或者非科研性質(zhì)的、非用于藥證申報(bào)使用等其他用途提供服務(wù)。	站點(diǎn)地圖隱私聲明
滬ICP備15051369號(hào)-4 上海工商滬公網(wǎng)安備31011502019417 滬(浦)應(yīng)急管危經(jīng)許[2021]201709(QFYS) 營(yíng)業(yè)執(zhí)照（三證合一）
Copyright ? 2013-2024 MedChemExpress. All Rights Reserved.

MedChemExpress (MCE) 只為有資質(zhì)的科研機(jī)構(gòu)、醫(yī)藥企業(yè)基于科學(xué)研究或藥證申報(bào)的用途提供醫(yī)藥研發(fā)服務(wù)，不為任何個(gè)人或者非科研性質(zhì)的、非用于藥證申報(bào)使用等其他用途提供服務(wù)。

站點(diǎn)地圖隱私聲明

滬ICP備15051369號(hào)-4

上海工商

滬公網(wǎng)安備31011502019417

滬(浦)應(yīng)急管危經(jīng)許[2021]201709(QFYS)

營(yíng)業(yè)執(zhí)照（三證合一）

成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

Lovastatin (Synonyms: 洛伐他汀; Mevinolin)

Customer Review

Other Forms of Lovastatin:

MCE 顧客使用本產(chǎn)品發(fā)表的 22 篇科研文獻(xiàn)